Article thumbnail

BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications

By Dora Dias-Santagata, Quynh Lam, Kathy Vernovsky, Natalie Vena, Jochen K. Lennerz, Darrell R. Borger, Tracy T. Batchelor, Keith L. Ligon, A. John Iafrate, Azra H. Ligon, David N. Louis and Sandro Santagata


Pleomorphic xanthoastrocytoma (PXA) is low-grade glial neoplasm principally affecting children and young adults. Approximately 40% of PXA are reported to recur within 10 years of primary resection. Upon recurrence, patients receive radiation therapy and conventional chemotherapeutics designed for high-grade gliomas. Genetic changes that can be targeted by selective therapeutics have not been extensively evaluated in PXA and ancillary diagnostic tests to help discriminate PXA from other pleomorphic and often more aggressive astrocytic malignancies are limited. In this study, we apply the SNaPshot multiplexed targeted sequencing platform in the analysis of brain tumors to interrogate 60 genetic loci that are frequently mutated in 15 cancer genes. In our analysis we detect BRAF V600E mutations in 12 of 20 (60%) WHO grade II PXA, in 1 of 6 (17%) PXA with anaplasia and in 1 glioblastoma arising in a PXA. Phospho-ERK was detected in all tumors independent of the BRAF mutation status. BRAF duplication was not detected in any of the PXA cases. BRAF V600E mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) analyzed, including 1 of 9 (11.1%) giant cell GBM (gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2011). A
  2. (2005). Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
  3. (2010). Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12.
  4. (2009). Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.
  5. (2008). An integrated genomic analysis of human glioblastoma multiforme.
  6. (2011). Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extracerebellar pilocytic astrocytoma.
  7. (2001). Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma.
  8. (2008). Analysis of the IDH1 codon 132 mutation in brain tumors.
  9. (2008). BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.
  10. (1997). Classification and grading of low-grade astrocytic tumors in children.
  11. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
  12. (1997). Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature.
  13. (2007). Diagnostic histopathology of tumors.
  14. (2002). Diagnostic pathology of nervous system tumours.
  15. (2009). Duplication of 7q34 in pediatric low-grade astrocytomas detected by highdensity single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.
  16. (1973). Fibrous xanthomas and xanthosarcomas of the meninges and the brain.
  17. (2007). Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
  18. (2002). Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
  19. (1999). Genetic profile of the giant cell glioblastoma.
  20. (2009). IDH1 and IDH2 mutations in gliomas.
  21. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma.
  22. (2009). Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation.
  23. (2010). Molecular classification of low-grade diffuse gliomas.
  24. (1996). Molecular genetic alterations in pleomorphic xanthoastrocytoma.
  25. (1997). Molecular genetic analysis of giant cell glioblastomas.
  26. (2010). Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis.
  27. (2005). Mutation analysis of B-RAF gene in human gliomas.
  28. (2004). Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.
  29. (2002). Mutations of the BRAF gene in human cancer.
  30. (2010). Narrative review: BRAF opens the door for therapeutic advances in melanoma.
  31. (2010). Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.
  32. (2009). Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
  33. (1997). p53 mutations versus EGF receptor expression in giant cell glioblastomas.
  34. (2006). Pediatric cerebellar pleomorphic xanthoastrocytoma with anaplastic features: a case of long-term survival after multimodality therapy.
  35. (2009). Pleomorphic xanthoastrocytoma as a component of a temporal lobe cystic ganglioglioma: a case report.
  36. (2010). Pleomorphic xanthoastrocytoma in children and adolescents.
  37. (1996). Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis.
  38. (1993). Pleomorphic Xanthoastrocytoma: The Birth of a Diagnosis and a Concept. Brain Pathology 3: 269–274.
  39. (1999). Pleomorphic xanthoastrocytoma: what do we really know about it?
  40. (2010). Practical surgical neuropathology: a diagnostic approach.
  41. (2009). Profiling critical cancer gene mutations in clinical tumor samples.
  42. (1996). Proliferative activity and p53 mutation as prognostic indicators in pleomorphic xanthoastrocytoma. A clinicopathologic study of six cases.
  43. (2009). RAF expression in human astrocytic tumors.
  44. (2010). Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.
  45. (2002). Surgical pathology of the nervous system and its coverings.
  46. (2008). Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.
  47. (2010). Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome.
  48. (2008). The Cancer Genome Atlas (TCGA) Research Network
  49. (2011). The Next Generation of Glioma Biomarkers:
  50. (1991). The pleomorphic xanthoastrocytoma and its differential diagnosis: a study of five cases.
  51. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
  52. (2001). The use of chemotherapy to facilitate surgical resection in pleomorphic xanthoastrocytoma: experience in a single case.
  53. (2010). Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.
  54. (2006). V600E BRaf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
  55. (2007). World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer.